Traws Pharma receives approval to proceed with Phase 2 COVID studies

Traws Pharma (TRAW) announced receipt from the Human Research Ethics Committee of approval to proceed with a Phase 2 study to evaluate ratutrelvir, a ritonavir-free treatment in newly diagnosed COVID subjects. “The first trial will enable Traws to compare ratutrelvir, a potential best in class ritonavir-free agent, against the current gold standard, PAXLOVID. Importantly, in second quarter 2025, Pfizer reported $427 million in sales for PAXLOVID, representing a 70% increase compared to the same period in the prior year,” said Iain Dukes, interim CEO. “This study will evaluate safety, as well as rates of infection, COVID symptoms, disease rebound and incidence of Long COVID. In addition, we will initiate a second trial to evaluate the safety and efficacy of ratutrelvir in PAXLOVID-ineligible patients, a population at risk for poor outcomes from COVID infection with few available treatment options. Our expectation is to be able to report the results of both these Phase 2 studies by year-end 2025.”